株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

細胞生存率アッセイの世界市場予測 2023年:MTTアッセイ、XTTアッセイ、カルセイン、レサズリン、フローサイトメトリー、スペクトロフォトメーター

Cell Viability Assays Market by Product (MTT Assay, XTT Assay, Calcein, Resazurin, Flow Cytometry, Spectrophotometer), Cell Type (Human, Animal, Microbial), Application (Basic Research, Stem Cell, Discovery & Development) - Global Forecast to 2023

発行 MarketsandMarkets 商品コード 696447
出版日 ページ情報 英文 231 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.56円で換算しております。
Back to Top
細胞生存率アッセイの世界市場予測 2023年:MTTアッセイ、XTTアッセイ、カルセイン、レサズリン、フローサイトメトリー、スペクトロフォトメーター Cell Viability Assays Market by Product (MTT Assay, XTT Assay, Calcein, Resazurin, Flow Cytometry, Spectrophotometer), Cell Type (Human, Animal, Microbial), Application (Basic Research, Stem Cell, Discovery & Development) - Global Forecast to 2023
出版日: 2018年09月05日 ページ情報: 英文 231 Pages
概要

世界の細胞生存率アッセイ市場は、2018年の27億8,000万米ドルから、2023年までに41億6,000万米ドルへ拡大すると予測され、この間は8.4%のCAGR (年間複合成長率) が見込まれています。慢性疾患・感染症の発症率の増加、研究用資金を獲得しやすくなったこと、研究におけるセルベースアッセイの需要の高まり、およびセルベース治療の開発に対する関心の高まりは、同市場の成長を促進しています。しかし、装置が高額であることは同市場の成長をある程度抑制すると見られています。

当レポートでは、世界の細胞生存率アッセイ市場について調査し、市場全体の構造や各種影響要因の分析、各セグメントおよび地域別の分析、競争環境、主要企業のプロファイルなど体系的な情報を提供しています。

FIGURE 15 CELL VIABILITY ASSAYS MARKET

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 細胞生存率アッセイ市場の概要
  • 細胞生存率アッセイ市場:地域概要
  • 地域ミックス:細胞生存率アッセイ市場
  • アジア太平洋の細胞生存率アッセイ市場:エンドユーザー & 国別
  • 細胞生存率アッセイ市場:先進市場 vs. 新興市場

第5章 市場概要

  • イントロダクション
  • 市場ダイナミクス
    • 市場成長促進因子
    • 市場成長抑制因子
    • 市場機会

第6章 細胞生存率アッセイ市場:製品別

  • イントロダクション
  • 消耗品
    • 試薬
    • アッセイキット
    • マイクロプレート
  • 装置
    • 自動セルカウンター
    • フローサイトメーター
    • スペクトロフォトメーター (分光高度計)
    • セルイメージング & 分析システム

第7章 細胞生存率アッセイ市場:セルタイプ別

  • イントロダクション
  • ヒト細胞
  • 動物細胞
  • 微生物細胞

第8章 細胞生存率アッセイ市場:用途別

  • イントロダクション
  • 創薬・開発
  • 基礎研究
  • 幹細胞研究
  • 臨床・診断用途
  • その他の用途

第9章 細胞生存率アッセイ市場:エンドユーザー別

  • イントロダクション
  • 医薬品・バイオテクノロジー企業
  • 大学・研究機関
  • 病院・診断ラボ
  • その他のエンドユーザー

第10章 細胞生存率アッセイ市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第11章 競合情勢

  • 概要
  • 市場シェア分析
  • 競合状況・動向

第12章 企業プロファイル

  • THERMO FISHER SCIENTIFIC
  • MERCK KGAA
  • BIO-RAD LABORATORIES
  • GE HEALTHCARE
  • DANAHER CORPORATION
  • BECTON, DICKINSON AND COMPANY
  • PROMEGA CORPORATION
  • BIOTIUM
  • ABCAM PLC
  • CREATIVE BIOARRAY
  • BIOTEK INSTRUMENTS
  • PERKINELMER

第13章 付録

図表

LIST OF TABLES

  • TABLE 1: CELL VIABILITY ASSAYS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • TABLE 2: INCREASE IN CANCER PATIENT POPULATION, BY CANCER TYPE
  • TABLE 3: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 4: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 5: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 6: CELL VIABILITY CONSUMABLES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 7: CELL VIABILITY REAGENTS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 8: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 9: CELL VIABILITY ASSAY KITS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 10: CELL VIABILITY ASSAY KITS OFFERED BY PROMINENT PLAYERS
  • TABLE 11: TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 12: TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 13: MTT ASSAY KITS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 14: OTHER TETRAZOLIUM ASSAY KITS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 15: RESAZURIN CELL VIABILITY ASSAY KITS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 16: CALCEIN-AM CELL VIABILITY ASSAY KITS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 17: OTHER ASSAY KITS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 18: CELL VIABILITY MICROPLATES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 19: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 20: CELL VIABILITY INSTRUMENTS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 21: AUTOMATED CELL COUNTERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 22: FLOW CYTOMETERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 23: SPECTROPHOTOMETERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 24: CELL IMAGING & ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 25: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 26: CELL VIABILITY ASSAYS MARKET FOR HUMAN CELLS, BY COUNTRY/REGION, 2016-2023 (USD MILLION)
  • TABLE 27: CELL VIABILITY ASSAYS MARKET FOR ANIMAL CELLS, BY COUNTRY/REGION, 2016-2023 (USD MILLION)
  • TABLE 28: CELL VIABILITY ASSAYS MARKET FOR MICROBIAL CELLS, BY COUNTRY/REGION, 2016-2023 (USD MILLION)
  • TABLE 29: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 30: CELL VIABILITY ASSAYS MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 31: CELL VIABILITY ASSAYS MARKET FOR BASIC RESEARCH, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 32: CELL VIABILITY ASSAYS MARKET FOR STEM CELL RESEARCH, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 33: CELL VIABILITY ASSAYS MARKET FOR CLINICAL AND DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 34: CELL VIABILITY ASSAYS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 35: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 36: CELL VIABILITY ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 37: CELL VIABILITY ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 38: CELL VIABILITY ASSAYS MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 39: CELL VIABILITY ASSAYS MARKET FOR OTHER END USERS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 40: CELL VIABILITY ASSAYS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 41: NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 42: NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 43: NORTH AMERICA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 44: NORTH AMERICA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 45: NORTH AMERICA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 46: NORTH AMERICA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 47: NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 48: NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 49: NORTH AMERICA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 50: US: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 51: US: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 52: US: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 53: US: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 54: US: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 55: US: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 56: US: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 57: US: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 58: CANADA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 59: CANADA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 60: CANADA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 61: CANADA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 62: CANADA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 63: CANADA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 64: CANADA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 65: CANADA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 66: EUROPE: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 67: EUROPE: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 68: EUROPE: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 69: EUROPE: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 70: EUROPE: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 71: EUROPE: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 72: EUROPE: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 73: EUROPE: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 74: EUROPE: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 75: GERMANY: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 76: GERMANY: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 77: GERMANY: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 78: GERMANY: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 79: GERMANY: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 80: GERMANY: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 81: GERMANY: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 82: GERMANY: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 83: FRANCE: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 84: FRANCE: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 85: FRANCE: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 86: FRANCE: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 87: FRANCE: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 88: FRANCE: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 89: FRANCE: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 90: FRANCE: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 91: UK: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 92: UK: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 93: UK: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 94: UK: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 95: UK: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 96: UK: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 97: UK: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 98: UK: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 99: ITALY: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 100: ITALY: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 101: ITALY: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 102: ITALY: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 103: ITALY: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 104: ITALY: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 105: ITALY: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 106: ITALY: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 107: SPAIN: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 108: SPAIN: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 109: SPAIN: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 110: SPAIN: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 111: SPAIN: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 112: SPAIN: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 113: SPAIN: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 114: SPAIN: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 115: ROE: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 116: ROE: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 117: ROE: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 118: ROE: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 119: ROE: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 120: ROE: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 121: ROE: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 122: ROE: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 123: ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 124: ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 125: ASIA PACIFIC: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 126: ASIA PACIFIC: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 127: ASIA PACIFIC: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 128: ASIA PACIFIC: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 129: ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 130: ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 131: ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 132: JAPAN: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 133: JAPAN: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 134: JAPAN: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 135: JAPAN: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 136: JAPAN: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 137: JAPAN: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 138: JAPAN: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 139: JAPAN: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 140: CHINA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 141: CHINA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 142: CHINA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 143: CHINA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 144: CHINA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 145: CHINA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 146: CHINA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 147: CHINA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 148: INDIA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 149: INDIA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 150: INDIA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 151: INDIA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 152: INDIA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 153: INDIA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 154: INDIA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 155: INDIA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 156: ROAPAC: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 157: ROAPAC: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 158: ROAPAC: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 159: ROAPAC: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 160: ROAPAC: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 161: ROAPAC: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 162: ROAPAC: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 163: ROAPAC: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 164: LATIN AMERICA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 165: LATIN AMERICA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 166: LATIN AMERICA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 167: LATIN AMERICA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 168: LATIN AMERICA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 169: LATIN AMERICA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 170: LATIN AMERICA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 171: LATIN AMERICA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 172: MIDDLE EAST & AFRICA: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 173: MIDDLE EAST & AFRICA: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 174: MIDDLE EAST & AFRICA: CELL VIABILITY ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 175: MIDDLE EAST & AFRICA: CELL VIABILITY TETRAZOLIUM REDUCTION ASSAY KITS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 176: MIDDLE EAST & AFRICA: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 177: MIDDLE EAST & AFRICA: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2016-2023 (USD MILLION)
  • TABLE 178: MIDDLE EAST & AFRICA: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2016-2023 (USD MILLION)
  • TABLE 179: MIDDLE EAST & AFRICA: CELL VIABILITY ASSAYS MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 180: GROWTH STRATEGY MATRIX (2015-2018)
  • TABLE 181: PRODUCT LAUNCHES, 2015-2018
  • TABLE 182: EXPANSIONS, 2015-2018
  • TABLE 183: ACQUISITIONS, 2015-2018
  • TABLE 184: OTHER STRATEGIES, 2015-2018

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: PRIMARY SOURCES
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
  • FIGURE 5: BOTTOM-UP APPROACH
  • FIGURE 6: TOP-DOWN APPROACH
  • FIGURE 7: DATA TRIANGULATION METHODOLOGY
  • FIGURE 8: CELL VIABILITY ASSAYS MARKET, BY PRODUCT, 2018 VS. 2023 (USD MILLION)
  • FIGURE 9: CELL VIABILITY INSTRUMENTS MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION)
  • FIGURE 10: CELL VIABILITY CONSUMABLES MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION)
  • FIGURE 11: CELL VIABILITY ASSAYS MARKET, BY CELL TYPE, 2018 VS. 2023 (USD MILLION)
  • FIGURE 12: CELL VIABILITY ASSAYS MARKET, BY APPLICATION, 2018 VS. 2023 (USD MILLION)
  • FIGURE 13: CELL VIABILITY ASSAYS MARKET, BY END USER, 2018 VS. 2023 (USD MILLION)
  • FIGURE 14: GEOGRAPHICAL SNAPSHOT OF THE CELL VIABILITY ASSAYS MARKET
  • FIGURE 15: RISING INCIDENCE AND PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES IS EXPECTED TO DRIVE MARKET GROWTH
  • FIGURE 16: THE US HELD THE LARGEST SHARE OF THE MARKET IN 2017
  • FIGURE 17: APAC TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2018-2023)
  • FIGURE 18: PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES ACCOUNTED FOR THE LARGEST SHARE OF THE APAC CELL VIABILITY ASSAYS MARKET IN 2017
  • FIGURE 19: DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD
  • FIGURE 20: REAGENTS TO DOMINATE THE CELL VIABILITY CONSUMABLES MARKET DURING THE FORECAST PERIOD
  • FIGURE 21: AUTOMATED CELL COUNTERS TO DOMINATE THE CELL VIABILITY INSTRUMENTS MARKET DURING THE FORECAST PERIOD
  • FIGURE 22: HUMAN CELLS SEGMENT TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2018-2023)
  • FIGURE 23: DRUG DISCOVERY AND DEVELOPMENT ESTIMATED TO BE THE LARGEST APPLICATION OF CELL VIABILITY ASSAYS IN 2018
  • FIGURE 24: CELL VIABILITY ASSAYS MARKET, BY END USER, 2018 VS. 2023 (USD MILLION)
  • FIGURE 25: CELL VIABILITY ASSAYS MARKET: GEOGRAPHIC SNAPSHOT (2017)
  • FIGURE 26: NORTH AMERICA: CELL VIABILITY ASSAYS MARKET SNAPSHOT
  • FIGURE 27: NIH FUNDING ON STEM CELL RESEARCH, 2013-2016 (USD BILLION)
  • FIGURE 28: EUROPE: CELL VIABILITY ASSAYS MARKET SNAPSHOT
  • FIGURE 29: ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET SNAPSHOT
  • FIGURE 30: PRODUCT LAUNCHES-KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2015 TO MAY 2018
  • FIGURE 31: CELL VIABILITY ASSAY KITS MARKET, BY KEY PLAYER, 2017
  • FIGURE 32: THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2017)
  • FIGURE 33: MERCK KGAA: COMPANY SNAPSHOT (2017)
  • FIGURE 34: BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2017)
  • FIGURE 35: GE HEALTHCARE: COMPANY SNAPSHOT (2017)
  • FIGURE 36: DANAHER CORPORATION: COMPANY SNAPSHOT (2017)
  • FIGURE 37: BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2017)
  • FIGURE 38: ABCAM PLC: COMPANY SNAPSHOT (2017)
  • FIGURE 39: PERKINELMER: COMPANY SNAPSHOT (2017)
目次
Product Code: BT 6577

"The global cell viability assays market is projected to grow at a CAGR of 8.4%."

The cell viability assays market is expected to reach USD 4.16 billion by 2023 from an estimated USD 2.78 billion in 2018, at a CAGR of 8.4%. The rising incidence and prevalence of chronic and infectious diseases, growing availability of funds for research and rising demand for cell-based assays in research, and increasing focus on the development of cell-based therapeutics are the key drivers for market growth. However, the high cost of instruments is expected to restrain the growth of this market to a certain extent during the forecast period.

"The human cells segment to witness the highest growth during the forecast period."

On the basis of cell type, the cell viability assays market is segmented into human cells, animal cells, and microbial cells. The human cells segment is expected to register the highest CAGR during the forecast period. Growth in this segment is mainly due to the growing investments by government bodies and private sector organizations in research activities that are focused on developing new treatments for various human diseases.

"The stem cell research applications segment to witness the highest growth during the forecast period."

On the basis of application, the cell viability assays market is segmented into drug discovery & development, basic research, stem cell research, clinical & diagnostic applications, and other applications. The stem cell research applications segment is expected to witness the highest CAGR owing to the increasing number of stem cell research activities and rising investments in stem cell research.

"APAC is projected to witness the highest growth during the forecast period."

North America is expected to account for the largest share of the global cell viability assays market in 2018. On the other hand, the APAC region is expected to witness the highest CAGR during the forecast period, owing to the increasing prevalence of chronic and infectious diseases in this region, large patient population, increasing healthcare spending, and growing interest of key players in APAC countries.

The breakdown of primary participants was as mentioned below:

  • By Company Type: Tier 1-45%, Tier 2-40%, and Tier 3-15%
  • By Designation: C-level-43%, Director Level-30%, and Others-27%
  • By Region: North America-32%, Europe-27%, Asia Pacific-19%, and RoW-22%

The prominent players in the global cell viability assays market are: Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Merck (Germany), GE Healthcare (US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), G-Biosciences (US), Creative Bioarray (US), Danaher Corporation (US), and Becton, Dickinson and Company (US).

Research Coverage:

The report analyzes the various cell viability products and their adoption pattern. It aims at estimating the market size and future growth potential of the global cell viability assays market for different segments such as products, cell types, applications, end users, and regions. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening the market.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global cell viability assays market
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the global cell viability assays market
  • Market Development: Comprehensive information on the lucrative emerging regions by product, cell type, application, end user, and region
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global cell viability assays market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players in the global cell viability assays market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY SOURCES
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY SOURCES
      • 2.1.2.1. Key data from primary sources
  • 2.2. MARKET SIZE ESTIMATION
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. MARKET SHARE ESTIMATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. CELL VIABILITY ASSAYS MARKET OVERVIEW
  • 4.2. CELL VIABILITY ASSAYS MARKET: GEOGRAPHIC OVERVIEW (2017)
  • 4.3. REGIONAL MIX: CELL VIABILITY ASSAYS MARKET (2018-2023)
  • 4.4. ASIA PACIFIC: CELL VIABILITY ASSAYS MARKET, BY END USER & COUNTRY (2017)
  • 4.5. CELL VIABILITY ASSAYS MARKET: DEVELOPED VS. DEVELOPING MARKETS

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Rising incidence and prevalence of chronic and infectious diseases
      • 5.2.1.2. Growing availability of funds for research
      • 5.2.1.3. Rising demand for cell-based assays in research
      • 5.2.1.4. Increasing focus on the development of cell-based therapeutics
    • 5.2.2. RESTRAINT
      • 5.2.2.1. High cost of instruments
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Emerging markets
      • 5.2.3.2. Growing focus on stem cell research

6. CELL VIABILITY ASSAYS MARKET, BY PRODUCT

  • 6.1. INTRODUCTION
  • 6.2. CONSUMABLES
    • 6.2.1. REAGENTS
    • 6.2.2. ASSAY KITS
      • 6.2.2.1. Tetrazolium reduction assay kits
        • 6.2.2.1.1. MTT assay kits
        • 6.2.2.1.2. Other tetrazolium assay kits
      • 6.2.2.2. Resazurin cell viability assay kits
      • 6.2.2.3. Calcein-AM cell viability assay kits
      • 6.2.2.4. Other assay kits
    • 6.2.3. MICROPLATES
  • 6.3. INSTRUMENTS
    • 6.3.1. AUTOMATED CELL COUNTERS
    • 6.3.2. FLOW CYTOMETERS
    • 6.3.3. SPECTROPHOTOMETERS
    • 6.3.4. CELL IMAGING & ANALYSIS SYSTEMS

7. CELL VIABILITY ASSAYS MARKET, BY CELL TYPE

  • 7.1. INTRODUCTION
  • 7.2. HUMAN CELLS
  • 7.3. ANIMAL CELLS
  • 7.4. MICROBIAL CELLS

8. CELL VIABILITY ASSAYS MARKET, BY APPLICATION

  • 8.1. INTRODUCTION
  • 8.2. DRUG DISCOVERY AND DEVELOPMENT
  • 8.3. BASIC RESEARCH
  • 8.4. STEM CELL RESEARCH
  • 8.5. CLINICAL AND DIAGNOSTIC APPLICATIONS
  • 8.6. OTHER APPLICATIONS

9. CELL VIABILITY ASSAYS MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.3. ACADEMIC & RESEARCH INSTITUTES
  • 9.4. HOSPITAL & DIAGNOSTIC LABORATORIES
  • 9.5. OTHER END USERS

10. CELL VIABILITY ASSAYS MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. US
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. GERMANY
    • 10.3.2. FRANCE
    • 10.3.3. UK
    • 10.3.4. ITALY
    • 10.3.5. SPAIN
    • 10.3.6. REST OF EUROPE
  • 10.4. ASIA PACIFIC
    • 10.4.1. JAPAN
    • 10.4.2. CHINA
    • 10.4.3. INDIA
    • 10.4.4. REST OF ASIA PACIFIC
  • 10.5. LATIN AMERICA
  • 10.6. MIDDLE EAST & AFRICA

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. MARKET SHARE ANALYSIS
    • 11.2.1. MARKET SHARE ANALYSIS: CELL VIABILITY ASSAY KITS MARKET
  • 11.3. COMPETITIVE SITUATION AND TRENDS
    • 11.3.1. PRODUCT LAUNCHES
    • 11.3.2. EXPANSIONS
    • 11.3.3. ACQUISITIONS
    • 11.3.4. OTHER STRATEGIES

12. COMPANY PROFILES (Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*

  • 12.1. THERMO FISHER SCIENTIFIC
  • 12.2. MERCK KGAA
  • 12.3. BIO-RAD LABORATORIES
  • 12.4. GE HEALTHCARE
  • 12.5. DANAHER CORPORATION
  • 12.6. BECTON, DICKINSON AND COMPANY
  • 12.7. PROMEGA CORPORATION
  • 12.8. BIOTIUM
  • 12.9. ABCAM PLC
  • 12.10. CREATIVE BIOARRAY
  • 12.11. BIOTEK INSTRUMENTS
  • 12.12. PERKINELMER

*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. AVAILABLE CUSTOMIZATIONS
  • 13.5. RELATED REPORTS
  • 13.6. AUTHOR DETAILS
Back to Top